Kyowa Kirin Presses On With Parkinson's Prospect In US As Successor Readied
Some 12 years after first NDA submission, Kyowa Hakko Kirin tries again to secure US approval for troubled Parkinson's drug, but some analysts remain unsure of commercial potential and the company itself is progressing a successor.
You may also be interested in...
Acorda's rise, fall, and attempt to rise again is a snapshot of the life of a biotech. The company reached the commercial-stage pinnacle with Ampyra, only to eventually see it fall away to patent challenges. Now, after big staff cuts, the company is hoping to prevail in the commercial market again, this time with Inbrija.
First new chemical entity for Parkinson's to clear FDA in 10 years, Xadago has a narrower indication than Teva's Azilect and similar pricing.
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.